JP2019530699A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019530699A5 JP2019530699A5 JP2019518406A JP2019518406A JP2019530699A5 JP 2019530699 A5 JP2019530699 A5 JP 2019530699A5 JP 2019518406 A JP2019518406 A JP 2019518406A JP 2019518406 A JP2019518406 A JP 2019518406A JP 2019530699 A5 JP2019530699 A5 JP 2019530699A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- alkoxy
- substituted
- bicyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 80
- 229910052799 carbon Inorganic materials 0.000 claims 65
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 63
- 125000003545 alkoxy group Chemical group 0.000 claims 63
- 125000002950 monocyclic group Chemical group 0.000 claims 60
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 48
- 125000000623 heterocyclic group Chemical group 0.000 claims 45
- 125000001072 heteroaryl group Chemical group 0.000 claims 30
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000005842 heteroatom Chemical group 0.000 claims 16
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 15
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 15
- 125000005843 halogen group Chemical group 0.000 claims 15
- 229910052757 nitrogen Inorganic materials 0.000 claims 15
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 15
- 229910052760 oxygen Inorganic materials 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 125000001424 substituent group Chemical group 0.000 claims 15
- 229910052717 sulfur Inorganic materials 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662405309P | 2016-10-07 | 2016-10-07 | |
| US62/405,309 | 2016-10-07 | ||
| PCT/US2017/054710 WO2018067432A1 (en) | 2016-10-07 | 2017-10-02 | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019530699A JP2019530699A (ja) | 2019-10-24 |
| JP2019530699A5 true JP2019530699A5 (enExample) | 2020-11-12 |
| JP7097875B2 JP7097875B2 (ja) | 2022-07-08 |
Family
ID=60117794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518406A Active JP7097875B2 (ja) | 2016-10-07 | 2017-10-02 | Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎアルファ応答の調節剤として有用なイミダゾピリダジン化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10836770B2 (enExample) |
| EP (1) | EP3523305B1 (enExample) |
| JP (1) | JP7097875B2 (enExample) |
| KR (1) | KR102531036B1 (enExample) |
| CN (1) | CN110036015B (enExample) |
| ES (1) | ES2902995T3 (enExample) |
| MA (1) | MA46453A (enExample) |
| WO (1) | WO2018067432A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR117398A1 (es) | 2018-03-12 | 2021-08-04 | Abbvie Inc | Inhibidores de la señalización mediada por tirosina cinasa 2 |
| JP7179161B2 (ja) | 2018-09-10 | 2022-11-28 | イーライ リリー アンド カンパニー | 乾癬および全身性エリテマトーデスの処置に有用なピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド誘導体 |
| AU2019339355A1 (en) * | 2018-09-13 | 2021-05-13 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| DK3870579T3 (da) | 2018-10-22 | 2025-01-02 | Alumis Inc | Tyk2-inhibitorer og anvendelser deraf |
| WO2020094363A1 (en) | 2018-11-05 | 2020-05-14 | Syngenta Participations Ag | Pesticidally active azole-amide compounds |
| AR117177A1 (es) | 2018-12-10 | 2021-07-14 | Lilly Co Eli | DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa |
| US11174264B2 (en) | 2019-01-23 | 2021-11-16 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| JP2022523434A (ja) | 2019-03-08 | 2022-04-22 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺有害生物的に活性なアゾール－アミド化合物 |
| CN113597424B (zh) | 2019-03-20 | 2025-04-18 | 先正达农作物保护股份公司 | 杀有害生物活性的唑酰胺化合物 |
| BR112021018822A2 (pt) | 2019-03-22 | 2021-11-23 | Syngenta Crop Protection Ag | Derivados de n-[1-(5-bromo-2-pirimidin-2-il-1,2,4-triazol-3-il)etil]-2-ciclopropil-6-(trifluorometil)piridina-4-carboxamida e compostos relacionados como inseticidas |
| CN114269336A (zh) | 2019-04-30 | 2022-04-01 | 细胞基因公司 | 包含阿普斯特和tyk2抑制剂的联合疗法 |
| WO2021162944A1 (en) | 2020-02-12 | 2021-08-19 | Eli Lilly And Company | Substituted 7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives |
| TWI810520B (zh) | 2020-02-12 | 2023-08-01 | 美商美國禮來大藥廠 | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺化合物 |
| EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| CN115916207A (zh) * | 2020-08-20 | 2023-04-04 | 轶诺(浙江)药业有限公司 | 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 |
| KR20230069984A (ko) * | 2020-09-16 | 2023-05-19 | 알루미스, 인크. | Tyk2 억제제 및 그의 용도 |
| US20240246944A1 (en) | 2021-03-16 | 2024-07-25 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Amino heteroaryl compounds and compositions |
| CA3236262A1 (en) | 2021-10-25 | 2023-05-04 | Isaac Marx | Tyk2 degraders and uses thereof |
| CN116655636A (zh) * | 2022-02-17 | 2023-08-29 | 上海轶诺药业有限公司 | 一类五元并六元杂环化合物及其作为蛋白激酶抑制剂的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| WO2009100375A1 (en) | 2008-02-06 | 2009-08-13 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
| EP2768509B1 (en) * | 2011-10-20 | 2017-03-22 | Glaxosmithkline LLC | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| CN105992768B (zh) * | 2013-12-10 | 2018-04-20 | 百时美施贵宝公司 | 用作IL‑12、IL‑23和/或IFNα响应的调节剂的咪唑并哒嗪化合物 |
| US10479793B2 (en) * | 2015-11-18 | 2019-11-19 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
-
2017
- 2017-10-02 US US16/339,744 patent/US10836770B2/en active Active
- 2017-10-02 MA MA046453A patent/MA46453A/fr unknown
- 2017-10-02 KR KR1020197012692A patent/KR102531036B1/ko active Active
- 2017-10-02 JP JP2019518406A patent/JP7097875B2/ja active Active
- 2017-10-02 ES ES17784774T patent/ES2902995T3/es active Active
- 2017-10-02 CN CN201780075174.6A patent/CN110036015B/zh active Active
- 2017-10-02 EP EP17784774.6A patent/EP3523305B1/en active Active
- 2017-10-02 WO PCT/US2017/054710 patent/WO2018067432A1/en not_active Ceased